Tocilizumab is thought to help suppress the hyperinflammatory response and reduce mortality, thus recommended for patients with human coronavirus if serum IL‐6 content is over 20 pg/mL despite prolonging neutropenia, even after the resolution of acute symptoms [19]. Here, IL6 is linked to neutropenia.